Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)

Journal of Clinical Microbiology

Volumn 48, Issue 9, 2010, Pages 3251-3257

  Espinel Ingroff, A ^a   Diekema, D J ^b   Fothergill, A ^c   Johnson, E ^d   Pelaez, T ^e   Pfaller, M A ^b   Rinaldi, M G ^c   Canton, E ^f   Turnidge, J ^g  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HPA Centre for Infections   (United Kingdom)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; BROTH DILUTION; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; FUNGUS ISOLATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STANDARD;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; EUROPE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES; UNITED STATES;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR;

EID: 77956796313     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00536-10     Document Type: Article

References (33)

1. Alcazar-Fuoli, L., E. Mellado, A. Alastruey-Izquierdo, M. Cuenca-Estrella, and J. L. Rodríguez-Tudela. 2009. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob. Agents Chemother. 53:4514-4517.
2. Baddley, J. W., K. A. Marr, D. R. Andes, T. J. Walsh, C. A. Kauffman, D. P. Kontoyiannis, I. Ito, S. A. Balajee, P. G. Pappas, and S. A. Mosser. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Survey Network. J. Clin. Microbiol. 47:3271-3275.
3. Barnes, P. D., and K. A. Marr. 2006. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect. Dis. Clin. North Am. 20:545-561.
4. Chen, J., H. Li, R. Li, D. Bu, and Z. Wan. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Dalhoff, A., P. G. Ambrose, and J. W. Mouton. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
7. Denning, D. W. 2006. Aspergillus and aspergillosis - progress on many fronts. Med. Mycol. 44:S1-S2.
8. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.
9. Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodríguez-Tudela. 2003. A point mutation in the 14α-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1224.
10. Espinel-Ingroff, A., M. Bartlett, V. Chaturvedi, M. Ghannoum, K. C. Hazen, M. A. Pfaller, M. G. Rinaldi, and T. J. Walsh. 2001. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob. Agents Chemother. 45:1828-1835.
11. Espinel-Ingroff, A., E. Johnson, and P. F. Troke. 2008. Activity of voriconazole, itraconazole and amphotericin B in vitro against 595 moulds from patients in the voriconazole phase III clinical studies. J. Antimicrob. Chemother. 61:616-620.
12. Garcia-Effron, G., E. Mellado, A. Gomez-Lopez, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodríguez-Tudela. 2005. Differences in interactions between azole drugs related to modifications in the 14-α sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:2119-2121.
13. Howard, S. J., D. Cerar, M. J. Anderson, A. Albarrag, M. C. Fisher, A. C. Pasqualotto,. M. Laverdiere, M. C. Arendrup, D. S. Perlin, and D. W. Denning. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
14. Kahlmeter, G., D. F. J. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, A. Österlund, A. Rodloff, M. Steinbakk, P. Urbaskova, and A. Vatopoulos. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:143-148.
15. Kaya, A. D., and N. Kiraz. 2007. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 50:447-450.
16. Krishnan-Natesan, S., P. H. Chandrasekar, G. J. Alangaden, and E. K. Manavathu. 2008. Molecular characterization of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int. J. Antimicrob. Agents 32:519-524.
17. Lass-Florl, C., A. Alastruey-Izquierdo, M. Cuenca-Estrella, S. Perkhofer, and J. L. Rodríguez-Tudela. 2009. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:794-795.
18. Mavridou, E., R. J. M. Bruggemann, W. J. G. Melchers, J. W. Mouton, and P. E. Verweij. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
19. Mellado, E., T. M. Diaz-Guerra, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438.
20. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, W. J. G. Melchers, P. E. Verweij, M. Cuenca-Estrella, and J. L. Rodríguez-Tudela. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
21. Osherov, N., D. P. Kontoyannis, A. Romans, and G. S. May. 2001. Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14-alpha-demethylase gene, pmdA. J. Antimicrob. Chemother. 48:75-81.
22. Pfaller, M. A., D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, A. Espinel-Ingroff, C. L. Fowler, E. M. Johnson, C. C. Knapp, M. R. Motyl, L. Ostrosky-Zeichner, D. J. Sheehan, and T. Walsh. 2009. Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
23. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, R. N. Jones, J. Turnidge, and D. J. Diekema. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
24. Rodriguez-Tudela, J. L., L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monson, and M. Cuenca-Estrella. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472.
25. Snelders, E., H. A. van der Lee, J. Kuijpers, A. J. Rijs, J. Varga, R. A. Samson, E. Mellado, A. R. Donders, W. J. Melchers, and P. E. Verweij. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
26. Turnidge, J., G. Kahmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
27. Turnidge, J., and D. L. Patterson. 2007. Setting and revising antibacterial breakpoints. Clin. Microbiol. Rev. 20:391-408.
28. Van den Brink, H. J., H. J. Van Nistelrooy, M. A. de Waard, C. A. van den Hondel, and R. F. van Gorcom. 1996. Increased resistance to 14-alpha-demethylase inhibitors (DMIs) in Aspergillus niger by coexpression of the Penicillium italicum eburicol 4-alpha-demethylase (cyp51) and the A. niger cytochrome P450 reductase (cypA). J. Biotechnol. 49:1318.
29. van der Linden, J. W. M., R. R. Jansen, D. Bresters, C. E. Visser, S. E. Geerlings, E. J. Kuijper, W. J. G. Melchers, and P. E. Verweij. 2009. Azoleresistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
30. Verweij, P. E., S. J. Howard, W. J. G. Melchers, and D. W. Denning. 2009. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
31. Verweij, P. E., E. Mellado, and W. J. G. Melchers. 2007. Multiple-triazole-resistance aspergillosis. N. Engl. J. Med. 356:1481-1483.
32. Verweij, P. E., M. F. Q. van den Bergh, P. M. Rath, B. E. dePaw, A. Voss, and J. F. M. Meis. 1999. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J. Clin. Microbiol. 37:1606-1609.
33. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.